CG On­col­o­gy touts in­ter­im Phase 3 blad­der can­cer da­ta, gears up to com­pete with Im­mu­ni­ty­Bio

An ex­per­i­men­tal on­colyt­ic virus ther­a­py de­vel­oped by CG On­col­o­gy helped clear tu­mors in 75% of blad­der can­cer pa­tients in a Phase 3 study.

The ther­a­py, known as cre­tosti­mo­gene grenade­norepvec, or cre­to for short, is a virus de­signed to in­fect and de­stroy tu­mor cells. It’s a form of im­munother­a­py — as the virus spreads through tu­mor cells and kills them, the rup­tured cells re­lease tiny can­cer mark­ers that alert im­mune cells, which join the at­tack.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER